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What is known on this topic What this paper adds 
- Recent studies have suggested a 
relationship between RDW and 
stroke  
- RDW is associated with 
cardiovascular mortality and all-
cause mortality 
- RDW is associated with risk of 
incident stroke independent of 
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Red cell distribution width (RDW), a measure of the variability in size of the circulating 
erythrocytes, is associated with cardiovascular morbidity and mortality. We aimed to 
investigate whether RDW was associated with incident stroke and case fatality in subjects 
recruited from the general population.  
Baseline characteristics were obtained from 25992 subjects participating in the fourth survey 
of the Tromsø Study, conducted in 1994/95. Incident stroke was registered from inclusion 
until December 31st 2010. Cox regression models were used to calculate hazard ratios (HR) 
with 95% Confidence Intervals (95% CI) for stroke, adjusted for age, sex, body mass index, 
smoking, haemoglobin level, white blood cell count, thrombocyte count, hypertension, total 
cholesterol, triglycerides, self-reported diabetes, and red blood cell count. During a median 
follow-up of 15.8 years, 1152 participants experienced a first-ever stroke. A 1% increment in 
RDW yielded a 13% higher risk of stroke (multivariable HR: 1.13, 95% CI: 1.07-1.20). 
Subjects with RDW in the highest quintile compared to the lowest had a 37% higher risk of 
stroke in multivariable analysis (HR: 1.37, 95% CI: 1.11-1.69). Subjects with RDW above the 
95-percentile had 55% higher risk of stroke compared to those in the lowest quintile (HR: 
1.55, 95% CI: 1.16-2.06). All risk estimates remained unchanged after exclusion of subjects 
with anaemia (n=1102). RDW was not associated with increased risk of death within one year 
or during the entire follow-up after an incident stroke. 
RDW is associated with incident stroke in a general population, independent of anaemia and 
traditional atherosclerotic risk factors.   
 






Red blood cell distribution width (RDW), an inexpensive and easy accessible measure of the 
size variability of circulating erythrocytes, is calculated by most automated blood cell 
counters. RDW gives the coefficient of variation of the red blood cell volume in percentage, 
and is the numeric equivalent to anisocytosis judged from a peripheral blood smear. 
Combined with mean corpuscular volume (MCV), RDW is traditionally used in the 
differential diagnosis of anaemia. Haematological diseases and conditions that result in 
premature release of red blood cells into the blood stream also lead to an increase in RDW (1-
3). 
Recent studies of various selected populations, including patients with heart failure (4-
6), patients undergoing percutaneous coronary intervention (7), and male patients referred for 
coronary angiography (8), have reported an association between RDW and all-cause 
mortality. Growing evidence is also supporting an association between RDW and 
cardiovascular morbidity and mortality (9-11). In large cohorts recruited from the general 
population, high RDW was associated with incident myocardial infarction and fatal coronary 
events (12, 13). A post hoc analysis of 4111 subjects with previous myocardial infarction 
from the Cholesterol and Recurrent Event (CARE) study reported a 2.6-fold higher risk of 
stroke among subjects with RDW in the highest compared to the lowest quartile (14). A case-
control study of 224 patients with first-ever ischemic stroke and 224 controls reported a dose-
response relation between RDW and risk of stroke, and subjects in the highest RDW quartile 
had a 5.9-fold higher risk of stroke than subjects in the lowest quartile (15). An association 
between RDW and stroke was also reported among 133 patients with stable heart failure 
followed for one year (16). In a registry based study of 41,140 subjects with atrial fibrillation, 





(17). Furthermore, RDW has been associated with both all-cause and cardiovascular death in 
subjects with a history of stroke (18, 19). 
Cerebrovascular events are the number one cause of permanent disability, and the third 
most common cause of death in the western world (20-22). Identification of novel biomarkers 
is an important step to improve risk stratification and thereby potentially prevent disease by 
targeted interventions. The impact of RDW on the risk of incident stroke in a general 
population remains unknown. Therefore, we set out to investigate whether elevated RDW was 
associated with a first-ever stroke and case-mortality in stroke patients in a large cohort 





Materials and Methods 
Study population 
Study participants were recruited from the fourth survey of the Tromsø Study, a single-centre 
prospective, population-based study, conducted in 1994-95. All inhabitants aged 25 years or 
older were invited. A total of 27158 attended, yielding a participation rate of 77%. The 
municipality of Tromsø is the largest in northern Norway, and is predominantly inhabited by 
Caucasians of Norwegian origin. The study population has been described in detail elsewhere 
(23). We excluded subjects without valid written consent to medical research (n=202), 
subjects with a history of stroke prior to the survey (n=342), and subjects who were lacking 
measurements of RDW (n=622). Hence, 25992 participants (12279 men and 13713 women) 
were enrolled in the present study. The study was approved by the regional committee for 
research ethics, and informed written consent was obtained from all participants.  
 
Measurements of cardiovascular risk factors 
Baseline information on cardiovascular risk factors was obtained through physical 
examinations, blood samples, and self-administered questionnaires (23).  
Blood samples were drawn from an antecubital vein into vacutainer tubes containing 
EDTA as an anticoagulant (K3-EDTA 40 μL, 0.37 mol/L per tube). For blood cell counts, 
including RDW, 5 mL of blood was drawn, and analyzed within 12 hours in an automated 
blood cell counter (Coulter Counter; Coulter Electronics, Luton, UK). The standard deviation 
of MCV was divided by the MCV and multiplied by 100 to give the RDW. The analytic 
variation coefficient of RDW was less than 3%.  
 
Lipid analyses were conducted on serum from non-fasting blood samples. The serum was 





used to measure triglycerides, total cholesterol, and high density lipoprotein (HDL) 
cholesterol, as previously described (24). All blood samples were analysed at the Department 
of Clinical Chemistry, University Hospital of North Norway.  
Blood pressure was recorded with an automatic device (Dinamap Vital Signs Monitor, 
1846, Critikon Inc., Tampa, FL, USA) by trained personnel. After two minutes rest in a seated 
position, three recordings were done on the upper right arm with two-minute intervals. The 
mean of the last two recordings was used in this report. Subjects were defined as hypertensive 
if they reported current use of blood pressure lowering medication, had systolic blood 
pressure ≥140mmHg, or diastolic blood pressure ≥90mmHg.   
Measurements of height and weight were conducted using electronic scales, with 
participants wearing light clothing and no shoes. Body mass index was calculated as the 
weight in kilograms divided by the square of height in meters. 
Information on daily smoking and diabetes was obtained from self-administered 
questionnaires. A study participant was defined as a daily smoker if he/she answered yes to 
any of the following three questions; “do you smoke cigarettes daily?”; “do you smoke 
cigars/cigarillos daily?”; or “do you smoke pipe daily?”. Study participants answering “no” to 
all three questions were defined as non-smokers. The question on diabetes read as follows: 




Stroke was defined according to the WHO definition as rapidly developing clinical signs of 
focal or global disturbance of cerebral function, with symptoms lasting 24 hours or longer or 
leading to death, and with no apparent cause other than vascular origin. The Norwegian 





registries. First-ever non-fatal and fatal strokes were identified by a search for the 
International Classification of Diseases (ICD) 9th Revision codes 430-438 and ICD 10th 
Revision codes I60-I69 in the diagnosis registries at the University Hospital of North Norway 
(diagnoses from outpatient clinics included), and the National Causes of Death Registry at 
Statistics Norway. The University Hospital of North Norway is the only hospital serving the 
community, the nearest hospital being located approx. 250 km away by road (148 by air). The 
Causes of Death Registry covers all subjects registered as inhabitants of Norway at the time of 
their death, without regard to whether the death took place in Norway or abroad. This ensured 
a complete follow-up status for all-cause mortality.   
All possible hospitalized and out-of hospital stroke events were validated by an 
independent endpoint committee. Hospital medical records were retrieved for case validation. 
Information from the National Causes of Death Registry and from death certificates was used 
to collect relevant information of the event from additional sources such as autopsy reports 
and records from nursing homes, ambulance services, and general practitioners. Event 
ascertainment followed a detailed protocol, according to established diagnostic criteria. Each 
case was reviewed separately. We also performed manual and/or electronic text searches in 
paper versions (used until 2001) and digital versions of hospital records for notes on stroke in 
all participants with a diagnosis of ICD-9 410-414, 798-799, and ICD-10 I20-I25, R96, R98, 
and R99. Person-time of follow-up was calculated from the date of enrolment in 1994-95 to 
the date when a stroke was first diagnosed, the date a participant died, the date a participant 
moved from the municipality of Tromsø, or the end of the study period, December 31st 2010, 
whichever came first. Data was censored from date of death from other causes than stroke 






Case-mortality was defined as overall death or death within one year after incident 
stroke. For these analyses, person-time was calculated from the date of first-ever stroke to the 
date of death, migration or study end (Dec 31, 2010) whichever came first.  
 
Statistical analyses 
Statistical analyses were carried out using STATA version 13.0 (Stata corporation, College 
station, TX, USA) and R (version 2.15.1 for Windows). The significance level was set to 
0.05. For categorical analyses, the study population was divided into quintiles based on 
baseline RDW values (Quintile 1: ≤12.3%, Quintile 2: 12.4-12.6%, Quintile 3: 12.7-12.9%, 
Quintile 4: 13.0-13.4%, and Quintile 5: ≥13.5%).  Additionally, a cut-off point was fixed at 
the 95th percentile (RDW values ≥14.4%). Age-adjusted baseline characteristics across 
quintiles of RDW were estimated using analysis of variance (ANOVA) for continuous 
variables and logistic regression for dichotomous variables. Student’s t-test and chi square test 
was used to assess mean differences of baseline characteristics between subjects with and 
without stroke. 
Crude incidence rates (IR) were calculated as the total number of events divided by the 
total person time, and expressed as number of events per 1000 person-years at risk. Cox 
proportional hazard regression models were used to estimate age- and sex-adjusted, and 
multivariable adjusted hazard ratios (HR) with 95% confidence intervals (CI) for stroke per 
1% increment in RDW, as well as across quintiles of RDW, or RDW above the 95th 
percentile. In the percentile-based analyses, the lowest RDW quintile was used as reference 
group. The multivariable analyses were divided into two models: Model 1 included age, sex, 
body mass index, daily smoking, haemoglobin, white blood cells, and platelet count. Model 2 
included the variables in Model 1, as well as hypertension, total cholesterol, triglycerides, 





confounders. The number of study participants in the different adjustment models varied 
slightly due to missing data for some of the co-variates (in total <2% missing).  
Additionally, the association between RDW and stroke was visualized by a 
generalized additive regression plot. In this plot, RDW (log-transformed) was modelled with a 
4-degrees of freedom smoothing spline fit in a Cox proportional hazard model using R. 
Moreover, a plot visualizing the multivariable adjusted cumulative hazard of stroke according 
to quintiles of RDW was made using the graphing function in Stata.   
In subgroup analyses, the association between RDW and risk of ischemic stroke was 
analysed separately, and HRs were estimated across quintiles of RDW using the same 
adjustment models as described above.  
Lastly, the one year and overall case-mortality rates after incident stroke were 
estimated according to categories of RDW. Confounder adjustments were assessed using the 
same models as described above, except for age-adjustments which were carried out using the 
subjects age at the time of the stroke, rather than their age at baseline. The estimates were also 
adjusted for the time interval between baseline RDW measurement and the incident stroke.  
The proportional hazards assumption was tested using Schoenfeld residuals, and no violation 
was found. Cross-product terms of RDW and sex, or RDW and age, were included in 
adjustment model 2 to test for statistical interactions. There were no sex or age interactions. 
 
Results 
A total of 1152 subjects, of whom 631 were men and 521 women, experienced a first-ever 
stroke during a total of 340 977 person-years of follow-up. The median follow-up time was 
15.8 years and the overall crude incidence rate of stroke was 3.38 (95% CI: 3.19-3.58) per 





Table 1 shows the age-adjusted distribution of baseline characteristics across quintiles 
of RDW. Age, the proportion of daily smokers, HDL cholesterol, white blood cell count and 
platelet count increased with increasing RDW, while haemoglobin levels and the proportion 
with self-reported diabetes mellitus decreased.  
Baseline characteristics of subjects who did (n=1152) and did not (n=24840) develop 
stroke during follow-up are shown in Table 2. Traditional cardiovascular risk factors such as 
age, systolic blood pressure, diastolic blood pressure, BMI, total cholesterol, triglycerides, as 
well as the proportion of males and subjects with diabetes or hypertension were higher in 
subjects who developed stroke compared to those who did not. The platelet count and the 
proportion of daily smokers were lower in subjects that experienced a future stroke compared 
to those who did not.  
Hazard ratios and incidence rates across quintiles of RDW are shown in Table 3. The 
incidence rate increased from 1.5 (95% CI: 1.3-1.8) per 1000 person-years in the lowest 
quintile, to 6.7 (95% CI: 6.1-7.5) per 1000 person-years in the highest quintile of RDW. High 
RDW was associated with increased risk of stroke in both age-and sex-adjusted and 
multivariable analysis. The hazard ratio for stroke was 1.48 (95% CI: 1.21-1.81) when 
comparing the highest and lowest quintile in age- and sex-adjusted analysis. The association 
was weakened, but remained significant after adjustments in Model 1 (HR: 1.39, 95% CI: 
1.13-1.71), and Model 2 (HR: 1.37, 95% CI: 1.11-1.69). Subjects with RDW above the 95-
percentile had 55% higher risk of stroke compared to those in the lowest quintile (Model 2: 
HR 1.55, 95% CI: 1.16-2.06). Multivariable adjusted cumulative hazards for stroke by 
increasing quintiles of RDW are shown in Figure 1. There was a dose-response relationship 
between quintiles of RDW and risk of stroke that progressed over time. 
The generalized additive plot showed a clear dose-response relationship between 





Cox-model, a 1% increase in RDW was associated with 13% higher risk of stroke after 
adjustment for age and sex  (HR: 1.13, 95% CI: 1.08-1.19). The risk estimate remained 
essentially similar after multivariable adjustments (Model 1 HR: 1.15, 95% CI: 1.09-1.21) and 
after additional adjustments for cardiovascular risk factors (Model 2: HR 1.13, 95% CI: 1.07-
1.20).  
In subgroup analyses, the risk estimates of ischemic stroke according to RDW 
quintiles were similar to those of total stroke (Table 3). Individuals in the highest RDW 
quintile had 30% higher risk of ischemic stroke (Model 2: HR 1.30, 95% CI: 1.04-1.64) 
compared with the reference group.  
The risk estimates remained essentially similar after exclusion of subjects with 
anaemia (n=1102) (Supplementary table 1). The risk of stroke by RDW was somewhat 
weakened when the analyses were restricted to non-smokers (Model 2 HR for quintile 5 vs. 
quintile 1: 1.27, 95% CI: 0.98-1.64) (Supplementary table 2). In analyses restricted to 
smokers, the risk was 60% increased for those with RDW in quintile 5 versus quintile 1 
(Model 2: HR 1.60, 95% CI: 1.07-2.49) (Supplementary table 2).  
A total of 680 of the subjects that suffered an incident stroke died during follow-up. 
Hazard ratios of case fatality are shown in Table 4. The crude mortality rate after stroke was 
140 (95% CI: 129-150) per 1000 person-years. Subjects in the highest RDW quintile had 96% 
higher risk of death compared with subjects in the lowest quintile (HR 1.96, 95% CI: 1.47-
2.61) in unadjusted analysis (data not shown). The risk estimate was substantially reduced, 
and no longer statistically significant, when applying adjustment Model 1: HR 1.28, 95% CI 
0.95-1.73, and Model 2: HR 1.23, 95% CI 0.91-1.67. Moreover, RDW was not associated 







Our study is, to the best of our knowledge, the first to explore the relationship between RDW 
and incident stroke, as well as case fatality, in a population-based cohort. RDW, both 
modelled as a categorical and continuous variable, was associated with increased risk of 
incident stroke after adjustment for traditional atherosclerotic risk factors. We found no 
association between RDW and risk of overall mortality or one-year mortality after incident 
stroke. 
Our finding of an association between RDW and risk of incident stroke in a general 
population is supported by results from observational studies in selected populations. In a 
study of 41140 subjects with atrial fibrillation, a 33% (HR: 1.33, 95% CI: 1.15-1.53) 
increased risk of stroke (1692 cases) was shown for subjects in the highest RDW quartile, as 
compared with the lowest (17). In 133 non-anaemic patients with stable chronic heart failure, 
patients who developed stroke during follow-up had significantly higher baseline RDW (16). 
A dose-response relationship between RDW and risk of stroke was found in a case-control 
study of 224 patients with incident ischemic stroke and 224 controls. Subjects in the highest 
RDW  quartile had an almost 6-fold higher risk of stroke compared with those in the lowest 
quartile in multivariable analysis (15).  In a post hoc analysis of subjects with previous 
myocardial infarction from the CARE study, the stroke risk was 2.6-fold higher in subjects 
with RDW in the highest compared with the lowest quartile (14). Similarly, a cross-sectional 
study of 2497 diabetic patients from the National Health and Nutrition Examination Survey 
(NHANES) reported that subjects in the highest RDW quartile had a 2.6-fold higher odds of 
stroke compared with subjects in the lowest quartile (25).  
 We did not find any association between RDW and all-cause mortality among patients 
with incident stroke. Several studies have, however, shown an association between RDW and 
all-cause mortality, as well as cardiovascular mortality, in subjects both with and without 





showed that RDW was associated with case fatality in subjects with coronary events (13). The 
risk of death on the day of the coronary event, as well as within 28 days after the coronary 
event, increased with increasing quartiles of RDW in multivariable analysis. However, there 
was no association between RDW and risk of non-fatal coronary events.  In a cohort study of 
3226 subjects from Taiwan no association between RDW and incident stroke or 
cardiovascular mortality was found, but a relationship of  RDW with all-cause mortality and 
non-cardiovascular mortality was reported (28). The reasons for the diverging results are not 
known, but may include differential impact of ethnicity on the associations or differential 
population characteristics.  
 In contrast to our findings, two previous studies have reported an association between 
RDW and mortality in subjects with known cerebrovascular disease. A study by Kim et al. 
reported that RDW was associated with poor functional outcome and all-cause mortality at 
three months, and one year after stroke onset (18). Contradictory, in an analysis of 1504 
patients with stroke from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL), 
elevated RDW levels were not associated with poor functional outcome (29). Results from the 
NHANES study showed that high baseline RDW in subjects with stroke predicted subsequent 
cardiovascular deaths (HR: 2.38, 95% CI: 1.41-4.01) and all-cause mortality (HR: 2.0, 95% 
CI: 1.25-3.20) (19). The apparent discrepant findings may rely on the time sequence of RDW 
measurement and the occurrence of stroke. In both studies reporting a relationship, RDW was 
measured when the subjects suffered the stroke, whereas we measured RDW on average 7.4 
years prior to the cerebrovascular event. Although our analyses were adjusted for time 
between baseline measurements and the incident stroke, the timing between RDW 
measurement, stroke and death could have influenced our findings. Other possible 
explanations for the diverging results may be different population characteristics, size of the 





 The mechanisms behind the observed relationship between elevated RDW and 
incident stroke remain uncertain. As RDW is a pure numeric concept calculated from the 
mean corpuscular volume, it is likely to assume that some underlying condition must be 
involved  
 Several studies support the theory that RDW is a marker of inflammation and 
increases in response to pro-inflammatory cytokines. This aligns well with the notion that 
inflammation plays an important role in atherogenesis, which is the principal cause of 
cardiovascular events.(30, 31) In a study of 3845 unselected outpatients, a significant trend 
was observed for increasing high sensitivity CRP levels and erythrocyte sedimentation rate 
across increasing quartiles of RDW.(32) The associations remained after exclusion of all 
subjects above 60 years of age. A correlation between RDW and CRP was also observed in 
overweight adolescents,(33) in subjects with hypertension,(34) and in patients with 
Alzheimer’s disease.(35) In patients with heart failure, an increase in interleukin-6 and sTNF-
receptor was observed with increasing tertiles of RDW.(36)  
Various inflammatory cytokines interact with the effect of erythropoietin on the bone 
marrow, which leads to hypoproliferation,(37) and the production of hepcidin, a regulator of 
iron homeostasis.(38) A reduced production of erythrocytes, and reduced serum iron levels 
due to increased hepcidin secretion, may potentially lead to anemia. With the anemia there 
will be an increase in RDW levels that could explain the link between RDW and 
inflammatory biomarkers, and the association between RDW and various inflammatory 
diseases. However, the results from our analyses showed that the risk estimates for stroke 
remained essentially similar after exclusion of anemic study participants. This gives reason to 
believe that the observed association in the present study was independent of the link between 





without other inflammatory markers, do not yet give precise enough information for use in 
clinical practice.(39, 40) For this, further studies are warranted. 
RDW might also increase due to iron deficiency independent of anaemia status. Iron 
deficiency causes increased levels of reactive oxygen species and a reduction in iron-
dependent scavenger functions that may promote inflammation (41). Oxidative stress plays an 
important role in the aetiology of atherosclerosis (42), and can potentially lead to an increase 
in RDW through an impact on both hematopoietic stem cells and the life span of red blood 
cells (43). Another way RDW might influence the development of atherosclerosis and 
subsequent cardiovascular events more directly is through pathologic changes in the 
erythrocyte membrane, as the size distribution may impact the way the erythrocytes are 
incorporated into atherosclerotic plaques. Accumulation of erythrocytes, rich in free 
cholesterol (44), influence both plaque growth and stability (45). We have recently shown that 
RDW was associated with plaque growth during 7 years of follow-up in a study of 4677 
subjects from the general population. The association between RDW and plaque growth was 
not dependent of traditional atherosclerotic risk factors, including hs-CRP (46). Our findings 
support the concept that the role of RDW in development and stability of atherosclerotic 
plaques, either through iron-deficiency or accumulation of erythrocytes, is an important 
component in the relationship between RDW and cardiovascular events.  
Atrial fibrillation is a well-established risk factor for stroke (47, 48). In a study of 
27124 subjects from the general population, there was a 33% increased risk of developing 
atrial fibrillation in the highest RDW quartile compared to the lowest (49). Thus, the observed 
relation between RDW and stroke could potentially be mediated by atrial fibrillation.  
A major strength of our study is the prospective, population-based design with a long 
follow-up time. The large number of participants with high attendance rate gives good 





stroke events, and only one hospital serving the Tromsø region, decreases the possibility of 
missed outcomes. All blood samples were analysed in the same laboratory, and well-
determined values of baseline characteristics allowed for adjustment for many potential 
confounders. Some limitations of the study merit consideration. There was only one 
measurement of RDW throughout the study period, which may have led to underestimation of 
the associations due to regression dilution bias. Finally, residual confounding cannot be 
completely ruled out. This may arise from lacking information on inflammatory biomarkers, 
kidney status, lung status, heart disease and other underlying diseases that might affect 
baseline RDW.  
 In conclusion, we found a relationship between increasing RDW and risk of incident 
stroke in a general population, both when RDW was modelled as a continuous and a 
categorical variable. The association remained after exclusion of subjects with anaemia, and 
after adjustments for traditional atherosclerotic risk factors. We found no association between 
RDW and risk of death after incident stroke.  Future studies are warranted to confirm the 
association between RDW and incident stroke in the general population and to unveil 
mechanisms linking RDW to risk of stroke.  
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Table 1 Age-adjusted baseline characteristics 
Age-adjusted baseline characteristics across quintiles of red cell distribution width. 




Table 2 Baseline characteristics stratified according to future development of stroke 
Baseline characteristics of study participants stratified according to future development of 
stroke, with p-value for differences between the groups. The values are reported as means ± 
standard deviation, or percentages with number in brackets.  
 
 
Table 3 Adjusted hazard ratios for stroke 
Adjusted hazard ratios for stroke across quintiles of red cell distribution width (RDW) 
Incidence rates (IR) and hazard ratios (HRs) with 95% confidence intervals (CI) for total 
stroke and ischemic stroke according to quintiles of RDW. 
 
 
Table 4 Adjusted hazard ratios for mortality 
Adjusted hazard ratios for overall mortality and mortality within one year after stroke. 
Incidence rates (IR) and hazard ratios (HRs) with 95% confidence intervals (CI) for case 








Cumulative hazard of stroke according to quintiles of RDW. The Tromsø Study, 1994-2010. 
The model is adjusted for age, sex, body mass index, smoking, haemoglobin, white blood 
cells, thrombocytes, hypertension, cholesterol, triglycerides, self-reported diabetes and red 




Dose-response relationship between RDW and risk of stroke obtained by generalized additive 
regression. The regression model is adjusted for age, sex, body mass index, smoking, 
haemoglobin, white blood cells, thrombocytes, hypertension, cholesterol, triglycerides, self-
reported diabetes and red blood cell count. The solid line shows HRs and the shaded area 
shows 95% CI. The density plot shows the distribution of RDW and the white vertical lines 






Table 1. Age-adjusted baseline characteristics 












RDW range 10.7-12.3 12.4-12.6 12.7-12.9 13.0-13.4 13.5-30.5 >14.3 
Age, years 40.7 ± 12.2 44.2 ± 13.7 46.7 ± 14.1 50.1 ± 15.1 53.6 ± 16.0 53.3 ± 16.6 
Sex,  % males 46.0 48.5 50.2 49.0 42.5 31.9 
Current smoking, % 28.2 (1842) 33.1 (1678) 37.0 (1736) 44.1 (2307) 46.8 (2090) 41.1 (591) 
Body mass index, kg/m2 25.0 ± 3.5 25.2 ± 3.7 25.2 ± 3.7 25.2 ± 3.9 25.2 ± 4.3 25.0 ± 4.4 
Systolic blood pressure, mmHg 134 ± 17 135 ± 19  134 ± 20 134 ± 21 134 ± 24 134 ± 24 
Diastolic blood pressure, mmHg 78 ± 11 78 ± 12  78 ± 12 78 ± 13 78 ± 14 78 ± 14 
Hypertension, % 33.4 (2182) 34.0 (1724) 33.0 (1549) 32.6 (1705) 34.3 (1532) 34.3 (494) 
Total cholesterol, mmol/L 5.96 ± 1.22 6.04 ± 1.28 6.08 ± 1.31 6.1 ± 1.32 6.03 ± 1.35 5.84 ± 1.28 
HDL cholesterol, mmol/L 1.48 ± 0.39 1.48 ± 0.40 1.49 ± 0.40 1.51 ± 0.41 1.55 ± 0.44 1.59 ± 0.45 
Triglycerides, mmol/L 1.6 ± 1.1 1.6 ± 1.1 1.6 ± 1.1 1.5 ± 1.0 1.4 ± 1.0 1.3 ± 0.8 
Self-reported diabetes, % 2.2 (144) 1.7 (86) 2.1 (99) 1.4 (73) 1.2 (54) 1.7 (24) 
White Blood cells, x109/L 6.86 ± 1.81 6.98 ± 1.92 7.13 ± 2.13 7.26 ± 2.01 7.43 ± 2.23 7.31 ± 2.49 
Thrombocytes, x109/L 249 ± 51 248 ± 52 250 ± 54 254 ± 55 264 ± 68 283 ± 81 
Red blood cells, x1012/L 4.63 ± 0.42 4.65 ± 0.41 4.65 ± 0.41 4.64 ± 0.41 4.60 ± 0.43 4.55 ± 0.45 
Haemoglobin, g/dL 14.2 ± 1.1 14.2 ± 1.1 14.1 ± 1.1 14.0 ± 1.1 13.5 ± 1.4 12.7 ± 1.6 





Table 2. Baseline characteristics stratified according to future development of stroke 
 
Stroke Without  With P value 
N  24840  1152  
Age, years 45.7 ± 14.4  64.0 ± 12.7 <0.001 
Sex, % males 46.9  53.5 <0.001 
RDW, % 12.9 ± 0.9  13.3 ± 1.1 <0.001 
Systolic Blood Pressure, mmHg 133 ± 19  155 ± 25 <0.001 
Diastolic Blood Pressure, mmHg 77 ± 12  87 ± 14 <0.001 
Hypertension, % 31.4 (7761)  73.5 (936) <0.001 
Body Mass Index, kg/m2 25.1 ± 3.8  26.5 ± 4.2 <0.001 
Total Cholesterol, mmol/L 6.0 ± 1.3  6.7 ± 1.3 <0.001 
High density lipoprotein cholesterol, mmol/L 1.5 ± 0.4  1.5 ± 0.4 0.008 
Triglycerides, mmol/L 1.5 ± 1.0  1.8 ± 1.1 <0.001 
Daily smoking, % 37.0 (9146)  35.5 (452) 0.053 
Self-reported diabetes % 1.5 (371)  5.4 (69) <0.001 
Haemoglobin (total), g/dL 14.0 ± 1.2  14.2 ± 1.2 <0.001 
Mean corpuscular volume, fL 88.8 ± 4.2  89.2 ± 4.4 <0.001 
Red blood cells, x1012/L 4.6 ± 0.4  4.7 ± 0.4 <0.001 
White blood cells, x109/L 7.1 ± 2.0  7.2 ± 1.9 0.2 





Table 3. Adjusted hazard ratios for stroke 
RDW Person  
years 
No of  
events 
Crude  
IR (95% CI) 
Age/sex adjusted 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Total stroke       
Quintile 1 87930 136 1.5 (1.3-1.8) Ref Ref  Ref  
Quintile 2 68196 169 2.5 (2.1-2.9) 1.08 (0.86-1.36) 1.06 (0.84-1.33) 1.06 (0.85-1.34) 
Quintile 3 62737 198 3.2 (2.7-3.6) 1.10 (0.88-1.37) 1.05 (0.84-1.32) 1.05 (0.84-1.31) 
Quintile 4 68405 287 4.2 (3.7-4.7) 1.11 (0.90-1.37) 1.06 (0.86-1.31) 1.07 (0.87-1.33) 
Quintile 5 53708 362 6.7 (6.1-7.5) 1.48 (1.21-1.81) 1.39 (1.13-1.71) 1.37 (1.11-1.69) 
P (trend)   <0.001 <0.001 0.002 0.003 
>95 percentile 14833 99 6.7 (5.5-8.1) 1.65 (1.27-2.15) 1.67 (1.26-2.20) 1.55 (1.16-2.06) 
Ischemic stroke       
Quintile 1 87930 123 1.4 (1.2-1.7) Ref Ref  Ref  
Quintile 2 68196 142 2.1 (1.8-2.5) 1.00 (0.79-1.28) 0.98 (0.77-1.25) 0.99 (0.77-1.26) 
Quintile 3 62737 172 2.7 (2.4-3.2) 1.05 (0.83-1.33) 1.01 (0.80-1.27) 1.00 (0.79-1.27) 
Quintile 4 68405 251 3.7 (3.2-4.2) 1.07 (0.86-1.34) 1.02 (0.82-1.27) 1.04 (0.83-1.30) 
Quintile 5 53708 310 5.8 (5.2-6.4) 1.40 (1.12-1.73) 1.30 (1.04-1.63) 1.30 (1.04-1.64) 
P (trend)   <0.001 0.001 0.009 0.010 
>95 percentile 14833 89 6.0 (4.9-7.4) 1.64 (1.24-2.16) 1.67 (1.24-2.23) 1.60 (1.18-2.17) 
Model 1: Age, sex, BMI, smoking, haemoglobin, white blood cell count, thrombocytes 





Table 4. Adjusted hazard ratios for mortality 
 
Model 1: Age at time of stroke, sex, BMI, smoking, haemoglobin, white blood cell count, thrombocytes 
Model 2: Model 1 + hypertension, cholesterol, triglycerides, self-reported diabetes, red blood cell count and time from baseline measurement to 
incident stroke
RDW N Person  
years 
No of  
deaths 
Crude IR  
(95% CI) 
Age/sex adjusted   
HR (95% CI) 
Model 1  
HR (95% CI) 
Model 2 
HR (95% CI) 
Overall mortality       
Quintile 1 136 662 58 88 (68-113) Ref Ref  Ref  
Quintile 2 168 745 79 116 (85-132) 0.96 (0.69-1.35) 0.91 (0.64-1.28) 0.89 (0.63-1.26) 
Quintile 3 196 906 108 119 (99-144) 1.05 (0.76-1.44) 1.01 (0.73-1.39) 1.02 (0.73-1.41) 
Quintile 4  285 1078 175 163 (141-189) 1.23 (0.91-1.66) 1.16 (0.85-1.57) 1.17 (0.85-1.59) 
Quintile 5 357 1499 260 174 (154-196) 1.30 (0.97-1.73) 1.28 (0.95-1.73) 1.32 (0.97-1.80) 
>95 percentile 98 403 78 194 (155-242) 1.31 (0.93-1.84) 1.33 (0.93-1.90) 1.34 (0.92-1.94) 
1 year mortality       
Quintile 1 136 116 20 172 (111-266) Ref Ref Ref 
Quintile 2 168 142 27 190 (130-277) 0.86 (0.48-1.54) 0.85 (0.47-1.52) 0.87 (0.48-1.57) 
Quintile 3 196 163 34 208 (149-291) 0.95 (0.54-1.64) 1.00 (0.57-1.75) 0.98 (0.56-1.72) 
Quintile 4 285 228 61 268 (208-344) 1.06 (0.64-1.76) 1.13 (0.67-1.89) 1.08 (0.64-1.82) 
Quintile 5 357 295 80 271 (218-337) 1.05 (0.64-1.73) 1.13 (0.67-1.88) 0.96 (0.56-1.62) 
>95 percentile 98 77 27 350 (240-511) 1.25 (0.70-2.25) 1.31 (0.71-2.41) 1.01 (0.53-1.93) 
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